Fig 1.
SliceOmatic tomovision analysis of the computed tomography scan of a male patient distinguishing the different context of Visceral Adipose Tissue (VAT), Intramuscular Adipose Tissue (IMAT), Subcutaneous Adipose Tissue (SAT) and skeletal muscle according to their differential Hounsfield Units (HU) references.
Table 1.
Baseline (At the beginning of immunotherapy) patient characteristics.
Fig 2.
Box-plots depicting the baseline* differential distributions (Mann Whitney U test) of A.
SFI (cm2/m2) between responders (CR or PR) and non-responders (SD or PD) to I-O B. SFI (cm2/m2) between patients who achieved disease control (CR or PR or SD) as result of I-O versus those who developed disease progression (PD) C. BMI (kg/m2) between patients who achieved disease control as result of I-O administration in comparison to those who developed disease progression and D. VFI (cm2/m2) between individuals who experienced disease control under I-O versus those who had disease progression. Abbreviations: I-O = Immunotherapy; BMI = Body mass index; VFI = Visceral Fat Index (At the level of 3rd lumbar vertebra); SFI = Subcutaneous Fat Index (At the level of 3rd lumbar vertebra); CR = Complete response; PR = Partial response; SD = Stable disease, PD = Progressive disease. *Baseline = At the beginning of immunotherapy.
Table 2.
Treatment and response characteristics.
Fig 3.
Kaplan-Meier curves demonstrating the effect of A.
Baseline*1 LSMI*2 values on PFS B. Baseline LSMI values on OS C. Baseline SFI*3 values on PFS D. Baseline SFI values on OS. Abbreviations: LSMI = Lumbar skeletal muscle index (At the level of 3rd lumbar vertebra); SFI = Subcutaneous Fat Index (At the level of 3rd lumbar vertebra); OS = Overall survival; PFS = Progression free survival. *1 Baseline: At the beginning of immunotherapy with PD-1/PD-L1 inhibitors. *2 LNL: Lower normal limit, 55 cm2/m2 for males and 39 cm2/m2 for females. *3 High and low classification for SFI represents above and below gender specific median value, respectively.
Table 3.
Univariate analysis using Cox regression method investigating the hazard ratios of the BMI*, IMFI, VFI and SFI as continuous nominal variables (cm2/m2) on PFS and OS.
Gender was used as a stratification factor.
Fig 4.
Forest plots demonstrating the hazard ratios and their 95% confidence intervals of the analyzed parameters on A.
Probability of disease progression B. Probability of death under treatment with ICIs. Abbreviations: BMI = Body mass index; PD-L1 = Programmed death ligand-1, ICI = Immune checkpoint inhibitor; LSMI: Lumbar skeletal muscle index (At the level of 3rd lumbar vertebra); LNL: Lower normal limit, 55 cm2/m2 for males and 39 cm2/m2 for females; IMFI = Intramuscular Fat Index (At the level of 3rd lumbar vertebra); VFI = Visceral Fat Index (At the level of 3rd lumbar vertebra); SFI = Subcutaneous Fat Index (At the level of 3rd lumbar vertebra). *1,2,3,4,5,6 SFI, VFI, IMFI, LSMI, PD-L1 and BMI values were calculated at the beginning of treatment with ICIs. *1,2,3 Low for SFI, VFI and IMFI means below gender specific median value.